These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 639829)

  • 41. Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses.
    Frabetti L; Marchesini B; Capucci A; Cavallini C; Gubelli S; Ambrosioni E; Magnani B
    Eur J Clin Pharmacol; 1986; 30(6):665-71. PubMed ID: 2429844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration.
    Touboul P; Atallah G; Kirkorian G; de Zuloaga C; Dufour A; Aymard MF; Lavaud P; Moleur P
    Am Heart J; 1986 Aug; 112(2):333-9. PubMed ID: 3526853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog.
    Boucher M; Chassaing C; Hamel JD; Poirier JM
    Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of duration of rapid ventricular pacing on ventricular refractoriness in the presence of propafenone and lidocaine.
    Stark U; Stark G; Kasper K; Schwarzl I; Decrinis M; Pilger E; Tritthart HA
    Pacing Clin Electrophysiol; 1997 Jan; 20(1 Pt 1):43-50. PubMed ID: 9121970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone.
    Doni F; Della Bella P; Kheir A; Manfredi M; Piemonti C; Staffiere E; Rimondini A; Fiorentini C
    Am J Cardiol; 1995 Dec; 76(17):1243-6. PubMed ID: 7503004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of anti-anginal drugs on AV-conduction in normal subjects.
    Neuss H; Nowak FG; Schlepper M; Wüsten B
    Arzneimittelforschung; 1974 Feb; 24(2):213-6. PubMed ID: 4150916
    [No Abstract]   [Full Text] [Related]  

  • 47. [Effect of the antiarrhythmic agent propaphenone on cardiac conduction. clinical studies using bundle of his electrography].
    Beck OA; Witt E; Hochrein H
    Z Kardiol; 1975 Feb; 64(2):179-87. PubMed ID: 238345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canine electrophysiology of encainide, a new antiarrhythmic drug.
    Sami M; Mason JW; Oh G; Harrison DC
    Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Electrophysiologic effects of propafenone.
    Seipel L
    Am Heart J; 1984 Dec; 108(6):1587-8. PubMed ID: 6507265
    [No Abstract]   [Full Text] [Related]  

  • 50. Electrophysiology and pharmacology of aprindine, encainide, and propafenone.
    Zipes DP; Prystowsky EN; Heger JJ
    Ann N Y Acad Sci; 1984; 432():201-9. PubMed ID: 6441495
    [No Abstract]   [Full Text] [Related]  

  • 51. [Propafenon, a new antiarrhythmic agent for the treatment of ectopic and rapid cardiac arrhythmias (author's transl)].
    Beck OA
    Med Klin; 1975 Jan; 70(3-2):95-101. PubMed ID: 48183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electrophysiologic and pharmacokinetic profile of the new antiarrhythmic drug TYB-3823 in humans.
    Crijns HJ; Oosterhuis B; Wiesfeld AC; De Bruin H; Mensink CK; Jonkman JH; Kozma C; Lie KI
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):1-6. PubMed ID: 7678662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes.
    Salerno DM; Granrud G; Sharkey P; Asinger R; Hodges M
    Am J Cardiol; 1984 Jan; 53(1):77-83. PubMed ID: 6362387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
    Klempt HW; Nayebagha A; Fabry E
    Z Kardiol; 1982 May; 71(5):340-9. PubMed ID: 6180562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
    Naccarella F; Bracchetti D; Palmieri M; Marchesini B; Ambrosioni E
    Am J Cardiol; 1984 Nov; 54(8):1008-14. PubMed ID: 6496321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Electrophysiologic study of propafenon in Wolff-Parkinson-White syndrome].
    Clémenty J; Sourdille N; Pedeboscq G; Bricaud H
    Ann Cardiol Angeiol (Paris); 1982; 31(5):351-5. PubMed ID: 7158983
    [No Abstract]   [Full Text] [Related]  

  • 57. Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart.
    Gillis AM; Kates RE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):708-12. PubMed ID: 3712276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Indications and risks of anti-arrhythmia treatment with propafenone (author's transl)].
    Beck OA; Hochrein H
    Dtsch Med Wochenschr; 1978 Aug; 103(32):1261-5. PubMed ID: 78793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Progress in arrhythmology].
    Furlanello F; Bettini R; Dal Forno P; Vergara G; Stefenelli C; Zuechi S; Inama G; Disertori M
    G Ital Cardiol; 1981; 11 Suppl 1():202-53. PubMed ID: 7035271
    [No Abstract]   [Full Text] [Related]  

  • 60. [Changes in the mechanical action of the isolated guinea pig heart induced by doses of propafenon capable of affecting the electrocardiogram].
    Tucci PJ; Cicogna AC; Spadaro J
    Arq Bras Cardiol; 1979 Sep; 33(3):229-32. PubMed ID: 543812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.